Relapsed/refractory patients

FIH results of TAK-169 in patients with RRMM

L: English

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Shaji Kumar, Mayo Clinic, Rochester, US, discusses the first-in-human results of the anti-CD38 dimeric fusion protein TAK-169 in patients with relapsed/refractory multiple myeloma.

Shaji Kumar discusses the anti-CD38 dimeric fusion protein TAK-169, he explains CD38 is already a therapeutically validated target in myeloma (daratumumab and ixazomib). Shaji Kumar also explains that TAK-169 is different from existing anti-CD38 as it is attached to a toxin, and has shown efficacy in other malignancies. He describes the first-in-human, dose-escalation trial design, and the patient inclusion criteria.